EUCTR2019-002591-14-GB进行中（未招募）1 期
The Fenofibrate And Microvascular Events in Type 1 diabetes Eye (FAME 1 Eye):A randomised trial to evaluate the efficacy on retinopathy and safety of fenofibrate in adults with type 1 diabetes. A multicentre double-blind placebo-controlled study in Australia and internationally - FAME 1 Eye
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participants meeting all of the following criteria will be considered for enrolment into the study:
- •1) Men or non-pregnant women (on acceptable contraception) with T1D* according to standard criteria;
- •*T1D defined as either (1) T1D diagnosed below 40 years of age and insulin therapy commencing within one year of T1D diagnosis, or (2) T1D diagnosed before, at or after 40 years of age along with:
- •i)Documented history of ketoacidosis, and/or
- •ii)Documented history of very low or undetectable C-peptide (fasting <200 nmol/L or 0.2 pmol/L), and/or
- •iii)Documented history of T1D related autoantibody/ies (anti-GAD, anti-A2, anti-ZnT8).
- •2) Age 18 years or over;
- •3) eGFR must exceed 30 ml/min/1.73m2;
- •4) Must have at least one eligible eye with non-proliferative retinopathy (ETDRS score 35-53 inclusive) confirmed by current retinal photography within the last 3 months (irrespective of prior laser therapy);
- •Note: Any eye having undergone prior pan-retinal laser therapy is not eligible, but prior focal, macular or grid laser does not exclude that eye from eligibility.
- •5) All types of insulin therapy, with no restriction by level of HbA1c;
- •6) Willing and able to comply with all study requirements, including treatment, assessment and clinic visit attendances;
- •7) Able to personally read and understand the Participant Information and Consent Form and provide written, signed and dated informed consent to participate in study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1)Definite indication for or contraindications to fibrate treatment (Other lipid drugs [e.g. statins, ezetimibe, fish oils] are allowed.);
- •2)Need for bilateral intra-ocular treatment or laser photocoagulation therapy within the next 3 months; (this exclusion only applies to retinal laser photocoagulation treatment onto the posterior pole i.e. laser correction of corneas for short-sightedness is NOT an exclusion criterion);
- •3)Prior bilateral pan-retinal photocoagulation (PRP) treatment for diabetic retinopathy;
- •4)Prior bilateral intra-ocular injection(s) within the last 6 months;
- •5)Bilateral cataract surgery within the last 6 months;
- •6)Planned bilateral cataract surgery within the next 12 months;
- •7)History of any other non-diabetic eye disease that is or is likely to affect bilateral vision;
- •8)History of photosensitive skin rash or myositis;
- •9)Abnormal thyroid function (untreated);
- •10)Liver function tests exceeding 3xULN;
- •11)Persistent elevated unexplained blood CPK level above normal range;
- •12)Documented fasting TG levels >6.5 mmol/L;
- •13)History of pancreatitis, DVT or pulmonary embolism;
- •14)Use of investigational drugs in the prior 8 weeks;
- •15)Any unstable condition in last 3 months including active sepsis, diabetic ketoacidosis;
- •16)MI, unstable angina, stroke or heart failure within last 6 months;
- •17)Diagnosed cancer with ongoing treatment or prognosis anticipated at <5 years;
- •18)Any obstacle to regular follow-up including scheduled clinic attendances;
- •19)Prior or planned organ transplantation (including islet cell) with subsequent continued immunosuppression therapy.
研究者
相似试验
招募中
3 期
The Fenofibrate And Microvascular Events in Type 1 diabetes Eye: A randomised trial to evaluate the efficacy on retinopathy and safety of fenofibrate in adults with type 1 diabete. A multicentre double-blind placebo-controlled study in Australia and internationallyEye disease (retinopathy) in type 1 diabetes mellitusDiabetic nephropathy in type 1 diabetes mellitusEye - Diseases / disorders of the eyeMetabolic and Endocrine - DiabetesRenal and Urogenital - Kidney diseaseACTRN12611000249954HMRC Clinical Trials Centre, University of Sydney450
招募中
不适用
Microvascular Complications in Patients with Type 1 DiabetesType 1 diabetes mellitusMetabolic and Endocrine - DiabetesACTRN12605000739617Sydney Diabetes Clinical Research Unit, Royal North Shore Hospital50
尚未招募
不适用
Microvascular changes and microvascular reactivity in stable patients with Chronic Obstructive Pulmonary Disease using non-invasive retinal imagingChronic Obstructive Pulmonary DiseaseNL-OMON26359VITO and CIRO246
已完成
不适用
Microvascular changes and microvascular reactivity in stable patients with Chronic Obstructive Pulmonary Disease using non-invasive retinal imagingchronic obstructive pulmonary diseasechronic lungdisease with persistent obstruction of the airways10006436NL-OMON45747Ciro+250
招募中
不适用
The assessment of microvascular alterations in renal transplant recipients with and without rejectiorejectionchronische allograft nefropathie10038430NL-OMON33397eids Universitair Medisch Centrum105